Another influential voice takes Bristol-Myers’ top execs to task as they scramble to shore up the big Celgene buyout

Brad Loncar is not a big fan of the executive teams at either Bristol-Myers Squibb or Celgene.

Today, as Bristol-Myers scrambled to win investors’ backing, the Loncar Cancer Immunotherapy ETF outlined why it would line up with the growing — though still marginal — opposition that has gathered around the mega-buyout since Wellington, with 8% of Bristol’s shares, said it would be voting against the deal. Loncar joins the activists at Starboard Value who have planted their flag with the rebellion.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 45,000+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->